MELANOMA STAGE IV
Clinical trials for MELANOMA STAGE IV explained in plain language.
Never miss a new study
Get alerted when new MELANOMA STAGE IV trials appear
Sign up with your email to follow new studies for MELANOMA STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to wipe out hidden melanoma cells before they return
Disease control Recruiting nowThis study is for people with high-risk melanoma who have had surgery to remove their cancer. It uses a blood test to find tiny bits of tumor DNA that might remain. Participants will receive either a standard immunotherapy or a combination of two immunotherapy drugs to see which …
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 01, 2026 17:26 UTC
-
New combo aims to revive immune attack in stubborn melanoma
Disease control Recruiting nowThis study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to checkpoint inhibitors. About 14 adults with stage III or IV melanoma will receive …
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Experimental virus therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called VET3-TGI, a virus designed to attack cancer cells and boost the immune system. It is for adults with advanced solid tumors that have not responded to standard therapies. The study aims to find a safe dose when given alone or com…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Engineered immune cells take on multiple metastatic cancers
Disease control Recruiting nowThis early-phase study tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a specific marker called NY-ESO-1. The therapy is given as a one-time infusion to adults with advanced or spreading cancers lik…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Hadassah Medical Organization • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New trial aims to stop melanoma return after surgery
Disease control Recruiting nowThis study is for people with advanced melanoma (stage III or IV) that has a BRAF V600 mutation. Participants first receive a combination of two targeted drugs (encorafenib and binimetinib) before surgery. After surgery, doctors check how much the tumor has responded. Based on th…
Matched conditions: MELANOMA STAGE IV
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New combo therapy targets Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 participants with stage III or IV melanoma will receive the drug combination. The goal is to see how m…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
Brain metastases trial: could radiation boost immunotherapy for advanced melanoma?
Disease control Recruiting nowThis study is for adults with stage IV melanoma that has spread to the brain. It compares two treatments: a combination of two immunotherapy drugs (ipilimumab and nivolumab) alone versus the same drugs plus targeted radiation to the brain tumors. The goal is to see if adding radi…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
CAR t patients monitored for years in new Follow-Up study
Knowledge-focused Recruiting nowThis study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma and leukemia. Researchers will track late side effects, infections, and disease relapse to understand long-term safety. Participants do not receive new treatment …
Matched conditions: MELANOMA STAGE IV
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC